Conclusion Of A Non Exclusive Discount Agreement According To Section 130A Paragraph 8 Sgb V For The Active Ingredient Ustekinumab Atc L04Ac05 Obo For The Period 01 08 2024 31 07 2025 Plus Extension Option 1X12 Months

Deadline: 05 Jun 2026

Germany

Ref. No.: 6369929

EMD:Ref Document

Bid Value: Ref Document

136 Days Left

Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Pegvisomant Atc H01Ax01 Obo For The Period 01 08 2024 31 07 2026

Deadline: 05 Jun 2026

Germany

Ref. No.: 6369748

EMD:Ref Document

Bid Value: Ref Document

136 Days Left

Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Fesoterodine Atc G04Bd11 Obg For The Period 01 08 2024 31 07 2026

Deadline: 05 Jun 2026

Germany

Ref. No.: 6369364

EMD:Ref Document

Bid Value: Ref Document

136 Days Left

Medicines Containing The Active Substance Guselkumab Atc L04Ac16

Deadline: 31 May 2026

Germany

Ref. No.: 6368757

EMD:Ref Document

Bid Value: Ref Document

131 Days Left

Qualification System For Cables And Wires

Deadline: 31 Dec 2099

Germany

Ref. No.: 6368089

EMD:Ref Document

Bid Value: Ref Document

27008 Days Left

Conclusion Of A Non Exclusive Discount Agreement According To Section 130A Paragraph 8 Sgb V For The Active Ingredient Lisdexamfetamine Atc N06Ba12 Obg For The Period 01 08 24 31 07 25 Plus Extension Option 1X12 Months

Deadline: 05 Jun 2026

Germany

Ref. No.: 6367992

EMD:Ref Document

Bid Value: Ref Document

136 Days Left

Open House Biologics Discount Agreements 2024 08 Darbepoetin Alfa

Deadline: 01 Aug 2026

Germany

Ref. No.: 6352753

EMD:Ref Document

Bid Value: Ref Document

193 Days Left

Army Rapid Capabilities And Critical Technologies Office Rccto Broad Agency Announcement Baa

Deadline: 18 Jun 2029

United States

Ref. No.: 6347893

EMD:Ref Document

Bid Value: Ref Document

1245 Days Left

2024 Department Of Homeland Security Dhs Directorate Of Science And Technology S T Long Range Broad Agency Announcement Lrbaa 24 01

Deadline: 31 May 2029

United States

Ref. No.: 6346114

EMD:Ref Document

Bid Value: Ref Document

1227 Days Left

Dla Emergent Iv Research And Development Program

Deadline: 12 Jun 2027

United States

Ref. No.: 6345486

EMD:Ref Document

Bid Value: Ref Document

508 Days Left

Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Omalizumab Atc R03Dx05 Obo For The Period 01 08 2024 31 07 2025 Plus Extension Option 1X12 Months

Deadline: 05 Jun 2026

Germany

Ref. No.: 6344888

EMD:Ref Document

Bid Value: Ref Document

136 Days Left

Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Colistin Atc J01Xb01 Obg For The Period 01 08 2024 31 07 2026

Deadline: 05 Jun 2026

Germany

Ref. No.: 6340118

EMD:Ref Document

Bid Value: Ref Document

136 Days Left

Medicines Containing The Active Substance Ustekinumab Atc L04Ac05

Deadline: 31 May 2026

Germany

Ref. No.: 6337480

EMD:Ref Document

Bid Value: Ref Document

131 Days Left

Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Albendazole Atc P02Ca03 Obg For The Period 01 08 2024 31 07 2026

Deadline: 05 Jun 2026

Germany

Ref. No.: 6337365

EMD:Ref Document

Bid Value: Ref Document

136 Days Left

Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Pomalidomide Atc L04Ax06 Obg For The Period 01 08 2024 31 07 2026

Deadline: 05 Jun 2026

Germany

Ref. No.: 6335525

EMD:Ref Document

Bid Value: Ref Document

136 Days Left

Filter Your Search

Tenders by Countries

Browse Popular Sectors

Projects by Regions

Funding Agency

Support

CONTACT DETAILS

Filter Your Search

FREE Trial plan for all new users!